Lugang Pharmaceutical (600789.SH) subsidiary moxifloxacin hydrochloride injection obtained drug registration certificate

Zhitong Finance App News, Lu Hang Pharmaceutical (600789.SH) issued an announcement. Recently, Shandong Lukang Pharmaceutical Group Saite Co., Ltd. (hereinafter referred to as “Sete”), a holding subsidiary of the company, received the “Drug Registration Certificate” (approval number: 2024S02369) for moxifloxacin hydrochloride injection issued by the State Drug Administration. The drug is a generic drug approved in 4 categories according to the new registration classification, and is considered to have passed the consistent evaluation of the quality and efficacy of generic drugs.

Moxifloxacin is an 8-methoxyfluoroquinolone antimicrobial with a broad spectrum of activity and bactericidal action. Moxifloxacin has shown broad-spectrum antibacterial activity against gram-positive bacteria, gram-negative bacteria, anaerobes, acidophilus and atypical microorganisms such as mycoplasma, chlamydia, and legionella. The mechanism of bactericidal action interferes with topoisomerase II and IV. Moxifloxacin hydrochloride sodium chloride injection has obtained the “Drug Registration Certificate”, which will further enrich Sete's product pipeline and enhance its market competitiveness.